SK19152000A3 - Test na prítomnosť neplodného vajíčka - Google Patents

Test na prítomnosť neplodného vajíčka Download PDF

Info

Publication number: SK19152000A3
Authority: SK; Slovakia
Prior art keywords: day; assay; inhibin; estradiol; increase
Prior art date: 1998-06-22

Application number

SK1915-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Svend Lindenberg

Anne Lis Mikkelsen

Original Assignee

Medi-Cult A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-22

Filing date

1999-06-22

Publication date

2001-12-03

1998-06-22 Priority claimed from DK199900885A external-priority patent/DK199900885A/da

1999-06-22 Application filed by Medi-Cult A/S filed Critical Medi-Cult A/S

2001-12-03 Publication of SK19152000A3 publication Critical patent/SK19152000A3/sk

Links

238000003556 assay Methods 0.000 title claims abstract description 43
230000035800 maturation Effects 0.000 claims abstract description 41
239000003550 marker Substances 0.000 claims abstract description 39
238000000338 in vitro Methods 0.000 claims abstract description 28
241000124008 Mammalia Species 0.000 claims abstract description 23
238000006243 chemical reaction Methods 0.000 claims abstract description 15
210000004369 blood Anatomy 0.000 claims abstract description 10
239000008280 blood Substances 0.000 claims abstract description 10
210000002700 urine Anatomy 0.000 claims abstract description 5
206010036790 Productive cough Diseases 0.000 claims abstract description 4
210000003802 sputum Anatomy 0.000 claims abstract description 4
208000024794 sputum Diseases 0.000 claims abstract description 4
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 75
229930182833 estradiol Natural products 0.000 claims description 73
229960005309 estradiol Drugs 0.000 claims description 71
108010067471 inhibin A Proteins 0.000 claims description 70
230000004720 fertilization Effects 0.000 claims description 34
238000012360 testing method Methods 0.000 claims description 22
229940088597 hormone Drugs 0.000 claims description 21
239000005556 hormone Substances 0.000 claims description 21
230000007423 decrease Effects 0.000 claims description 13
208000021267 infertility disease Diseases 0.000 claims description 11
230000004044 response Effects 0.000 claims description 6
230000028327 secretion Effects 0.000 claims description 6
150000002632 lipids Chemical class 0.000 claims description 4
102000004190 Enzymes Human genes 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 3
150000007523 nucleic acids Chemical class 0.000 claims description 3
108020004707 nucleic acids Proteins 0.000 claims description 3
102000039446 nucleic acids Human genes 0.000 claims description 3
241000288906 Primates Species 0.000 claims description 2
108090000623 proteins and genes Proteins 0.000 claims description 2
102000004169 proteins and genes Human genes 0.000 claims description 2
238000003018 immunoassay Methods 0.000 claims 1
230000035935 pregnancy Effects 0.000 abstract description 30
238000002513 implantation Methods 0.000 abstract description 13
238000003744 In vitro fertilisation Methods 0.000 abstract description 4
210000004291 uterus Anatomy 0.000 abstract description 4
210000000287 oocyte Anatomy 0.000 description 97
235000013601 eggs Nutrition 0.000 description 74
206010003504 Aspiration Diseases 0.000 description 57
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 47
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 47
229940028334 follicle stimulating hormone Drugs 0.000 description 47
238000011282 treatment Methods 0.000 description 27
210000002966 serum Anatomy 0.000 description 25
230000027758 ovulation cycle Effects 0.000 description 22
239000000523 sample Substances 0.000 description 21
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 17
238000002604 ultrasonography Methods 0.000 description 17
230000000694 effects Effects 0.000 description 16
238000002474 experimental method Methods 0.000 description 14
238000011161 development Methods 0.000 description 12
230000018109 developmental process Effects 0.000 description 12
238000000034 method Methods 0.000 description 12
108010067479 inhibin B Proteins 0.000 description 11
230000000638 stimulation Effects 0.000 description 11
230000013020 embryo development Effects 0.000 description 10
239000003112 inhibitor Substances 0.000 description 10
210000002257 embryonic structure Anatomy 0.000 description 9
210000004696 endometrium Anatomy 0.000 description 9
229960003387 progesterone Drugs 0.000 description 9
210000004027 cell Anatomy 0.000 description 8
210000001672 ovary Anatomy 0.000 description 8
239000000186 progesterone Substances 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
230000002357 endometrial effect Effects 0.000 description 7
230000003054 hormonal effect Effects 0.000 description 7
230000021121 meiosis Effects 0.000 description 7
230000000740 bleeding effect Effects 0.000 description 6
230000002175 menstrual effect Effects 0.000 description 6
230000016087 ovulation Effects 0.000 description 6
241000283086 Equidae Species 0.000 description 5
102000006771 Gonadotropins Human genes 0.000 description 5
108010086677 Gonadotropins Proteins 0.000 description 5
208000007466 Male Infertility Diseases 0.000 description 5
230000006907 apoptotic process Effects 0.000 description 5
239000000262 estrogen Substances 0.000 description 5
239000002622 gonadotropin Substances 0.000 description 5
229940094892 gonadotropins Drugs 0.000 description 5
210000002503 granulosa cell Anatomy 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000031864 metaphase Effects 0.000 description 5
238000012544 monitoring process Methods 0.000 description 5
230000008569 process Effects 0.000 description 5
229940011871 estrogen Drugs 0.000 description 4
230000003325 follicular Effects 0.000 description 4
108010006578 follitropin alfa Proteins 0.000 description 4
229940057854 gonal f Drugs 0.000 description 4
239000002609 medium Substances 0.000 description 4
230000002611 ovarian Effects 0.000 description 4
238000001558 permutation test Methods 0.000 description 4
210000004508 polar body Anatomy 0.000 description 4
241000282693 Cercopithecidae Species 0.000 description 3
108010004250 Inhibins Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
XJDFBLQCLSBCGQ-UHFFFAOYSA-N anthracene-1-carbaldehyde Chemical compound C1=CC=C2C=C3C(C=O)=CC=CC3=CC2=C1 XJDFBLQCLSBCGQ-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000008144 egg development Effects 0.000 description 3
230000002124 endocrine Effects 0.000 description 3
230000012010 growth Effects 0.000 description 3
239000000893 inhibin Substances 0.000 description 3
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000011835 investigation Methods 0.000 description 3
230000029849 luteinization Effects 0.000 description 3
210000001161 mammalian embryo Anatomy 0.000 description 3
230000031877 prophase Effects 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
230000011664 signaling Effects 0.000 description 3
230000009469 supplementation Effects 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
238000012546 transfer Methods 0.000 description 3
238000011269 treatment regimen Methods 0.000 description 3
241000283690 Bos taurus Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
108010020661 Profasi Proteins 0.000 description 2
206010042573 Superovulation Diseases 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000008339 endometrial blood flow Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000001794 hormone therapy Methods 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000000509 infertility Diseases 0.000 description 2
230000036512 infertility Effects 0.000 description 2
231100000535 infertility Toxicity 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000009027 insemination Effects 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000003921 oil Substances 0.000 description 2
210000002394 ovarian follicle Anatomy 0.000 description 2
230000011599 ovarian follicle development Effects 0.000 description 2
239000000813 peptide hormone Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000009597 pregnancy test Methods 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
108010080511 serum sodium transport inhibitor Proteins 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000003104 tissue culture media Substances 0.000 description 2
VOXZDWNPVJITMN-QXDIGNSFSA-N (8s,9r,13r,14r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@@H]3CC[C@@](C)([C@@H](CC4)O)[C@H]4[C@H]3CCC2=C1 VOXZDWNPVJITMN-QXDIGNSFSA-N 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
101710150365 Albumin-1 Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
241000269350 Anura Species 0.000 description 1
108010037003 Buserelin Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
208000026351 Fallopian Tube disease Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000007984 Female Infertility Diseases 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021928 Infertility female Diseases 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000009328 Perro Species 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
206010036049 Polycystic ovaries Diseases 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
241000700159 Rattus Species 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000488 activin Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
229960002719 buserelin Drugs 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000003756 cervix mucus Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000007705 chemical test Methods 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
210000004246 corpus luteum Anatomy 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
210000001771 cumulus cell Anatomy 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000005786 degenerative changes Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
201000003511 ectopic pregnancy Diseases 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229960001348 estriol Drugs 0.000 description 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000008570 general process Effects 0.000 description 1
210000001667 gestational sac Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
238000007689 inspection Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000010311 mammalian development Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000008627 meiotic prophase Effects 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
230000008182 oocyte development Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
208000025661 ovarian cyst Diseases 0.000 description 1
230000000624 ovulatory effect Effects 0.000 description 1
210000004681 ovum Anatomy 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
230000036407 pain Effects 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000006259 progesterone secretion Effects 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035752 proliferative phase Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
229940076788 pyruvate Drugs 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
229960002385 streptomycin sulfate Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
230000014616 translation Effects 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Organic Chemistry (AREA)
Pathology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Pregnancy & Childbirth (AREA)
Developmental Biology & Embryology (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
General Engineering & Computer Science (AREA)
Reproductive Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Investigating Or Analysing Biological Materials (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Steroid Compounds (AREA)
Meat, Egg Or Seafood Products (AREA)
Stringed Musical Instruments (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Diaphragms For Electromechanical Transducers (AREA)

SK1915-2000A 1998-06-22 1999-06-22 Test na prítomnosť neplodného vajíčka SK19152000A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9011598P	1998-06-22	1998-06-22
DK199900885A DK199900885A (da)		1998-06-22	Fremgangsmåde for tildeling af et vilkårligt beløb på en given taletidskortkonto
PCT/DK1999/000344 WO1999067644A1 (en)	1998-06-22	1999-06-22	Assay to indicate the presence of non-fertilisable ova

Publications (1)

Publication Number	Publication Date
SK19152000A3 true SK19152000A3 (sk)	2001-12-03

Family

ID=26064838

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1915-2000A SK19152000A3 (sk)	1998-06-22	1999-06-22	Test na prítomnosť neplodného vajíčka

Country Status (23)

Country	Link
US (2)	US20020115211A1 (de)
EP (2)	EP1090300B1 (de)
JP (1)	JP2002519640A (de)
CN (2)	CN1607391A (de)
AT (1)	ATE407363T1 (de)
AU (2)	AU760165B2 (de)
BR (1)	BR9911470A (de)
CA (2)	CA2335632A1 (de)
DE (1)	DE69939468D1 (de)
EE (1)	EE200000763A (de)
ES (1)	ES2313785T3 (de)
HR (1)	HRP20000888A2 (de)
HU (1)	HUP0103392A2 (de)
ID (1)	ID27197A (de)
IL (2)	IL140394A0 (de)
IS (1)	IS5768A (de)
NO (2)	NO20006519L (de)
NZ (1)	NZ509451A (de)
PL (1)	PL345318A1 (de)
RU (1)	RU2227916C2 (de)
SK (1)	SK19152000A3 (de)
TR (1)	TR200003830T2 (de)
WO (2)	WO1999067644A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003076600A2 (en)	2002-03-08	2003-09-18	Mcgill University	In vitro maturation of immature human oocytes
WO2003106662A1 (en) *	2002-06-01	2003-12-24	KØBENHAVNS AMTS SYGEHUS, Herlev	In vitro fertilisation
JP5144073B2 (ja) *	2003-11-26	2013-02-13	メルクセローノソシエテアノニム	卵母細胞の成熟のためのｉｌ−６−型サイトカインの使用
US20070020755A1 (en) *	2005-07-07	2007-01-25	Teresa Woodruff	Stage specific follicle maturation systems
CN103275930B (zh) *	2013-06-20	2014-07-09	江苏皓康生物医药科技有限公司	一种卵母细胞体外成熟培养液及其制备方法
RU2708199C2 (ru) *	2014-06-10	2019-12-04	Полибайосепт Аб	Культуральная среда для клеточной иммунотерапии
WO2017143412A1 (en) *	2016-02-24	2017-08-31	Universidade Estadual Paulista "Júlioo De Mesquita Filho" - Unesp	Follicular system for in vitro oocyte maturation and kit
CN110628705A (zh) *	2019-10-22	2019-12-31	山东畜牧兽医职业学院	一种驴胚胎冲洗液及其应用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4614715A (en) *	1982-05-14	1986-09-30	The Board Of Trustees Of The University Of Illinois	Predictive test for impending ovulation in mammals
RU2013989C1 (ru) *	1991-08-13	1994-06-15	Борис Васильевич Леонов	Способ определения овуляции
GB9217866D0 (en) *	1992-08-21	1992-10-07	Unilever Plc	Monitoring method
JPH09506713A (ja) *	1993-12-16	1997-06-30	アボツト・ラボラトリーズ	女性の妊娠可能期を知る方法および手段
GB9410345D0 (en) *	1994-05-24	1994-07-13	Univ Oxford Brookes	Method of genetic testing
GB9603326D0 (en) *	1996-02-16	1996-04-17	Royal Free Hosp School Med	Predictive assay
DE69619236D1 (de) *	1996-09-27	2002-03-21	Unilever Plc	Überwachungsverfahren
GB9625175D0 (en) *	1996-12-04	1997-01-22	Medi Cult As	Serum-free cell culture media

1999
- 1999-06-22 ID IDW20010153A patent/ID27197A/id unknown
- 1999-06-22 DE DE69939468T patent/DE69939468D1/de not_active Expired - Lifetime
- 1999-06-22 EP EP99926293A patent/EP1090300B1/de not_active Expired - Lifetime
- 1999-06-22 CN CNA2004100489940A patent/CN1607391A/zh active Pending
- 1999-06-22 WO PCT/DK1999/000344 patent/WO1999067644A1/en not_active Ceased
- 1999-06-22 WO PCT/DK1999/000345 patent/WO1999067365A1/en not_active Ceased
- 1999-06-22 HR HR20000888A patent/HRP20000888A2/hr not_active Application Discontinuation
- 1999-06-22 AT AT99926293T patent/ATE407363T1/de not_active IP Right Cessation
- 1999-06-22 IL IL14039499A patent/IL140394A0/xx unknown
- 1999-06-22 RU RU2001101921/15A patent/RU2227916C2/ru not_active IP Right Cessation
- 1999-06-22 AU AU43604/99A patent/AU760165B2/en not_active Ceased
- 1999-06-22 CN CNB998099309A patent/CN1161615C/zh not_active Expired - Fee Related
- 1999-06-22 SK SK1915-2000A patent/SK19152000A3/sk unknown
- 1999-06-22 PL PL99345318A patent/PL345318A1/xx not_active Application Discontinuation
- 1999-06-22 NZ NZ509451A patent/NZ509451A/xx not_active IP Right Cessation
- 1999-06-22 ES ES99926293T patent/ES2313785T3/es not_active Expired - Lifetime
- 1999-06-22 CA CA002335632A patent/CA2335632A1/en not_active Abandoned
- 1999-06-22 TR TR2000/03830T patent/TR200003830T2/xx unknown
- 1999-06-22 EP EP99926294A patent/EP1088056A1/de not_active Withdrawn
- 1999-06-22 AU AU43605/99A patent/AU4360599A/en not_active Abandoned
- 1999-06-22 EE EEP200000763A patent/EE200000763A/xx unknown
- 1999-06-22 JP JP2000556250A patent/JP2002519640A/ja active Pending
- 1999-06-22 BR BR9911470-4A patent/BR9911470A/pt not_active IP Right Cessation
- 1999-06-22 CA CA002335793A patent/CA2335793A1/en not_active Abandoned
- 1999-06-22 IL IL14028399A patent/IL140283A0/xx unknown
- 1999-06-22 HU HU0103392A patent/HUP0103392A2/hu unknown
2000
- 2000-12-12 IS IS5768A patent/IS5768A/is unknown
- 2000-12-20 NO NO20006519A patent/NO20006519L/no not_active Application Discontinuation
- 2000-12-21 NO NO20006545A patent/NO20006545L/no not_active Application Discontinuation
- 2000-12-22 US US09/746,633 patent/US20020115211A1/en not_active Abandoned
- 2000-12-22 US US09/746,656 patent/US20010028878A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2335793A1 (en)	1999-12-29
AU4360499A (en)	2000-01-10
CN1607391A (zh)	2005-04-20
JP2002519640A (ja)	2002-07-02
EP1090300A1 (de)	2001-04-11
CA2335632A1 (en)	1999-12-29
IL140394A0 (en)	2002-02-10
IS5768A (is)	2000-12-12
HUP0103392A2 (hu)	2002-01-28
AU760165B2 (en)	2003-05-08
HRP20000888A2 (en)	2001-12-31
BR9911470A (pt)	2001-03-20
CN1161615C (zh)	2004-08-11
EP1090300B1 (de)	2008-09-03
EP1088056A1 (de)	2001-04-04
EE200000763A (et)	2002-06-17
WO1999067644A1 (en)	1999-12-29
NO20006519D0 (no)	2000-12-20
ES2313785T3 (es)	2009-03-01
NZ509451A (en)	2003-03-28
WO1999067365A1 (en)	1999-12-29
NO20006519L (no)	2001-02-21
PL345318A1 (en)	2001-12-03
IL140283A0 (en)	2002-02-10
RU2227916C2 (ru)	2004-04-27
DE69939468D1 (de)	2008-10-16
US20010028878A1 (en)	2001-10-11
NO20006545D0 (no)	2000-12-21
CN1313951A (zh)	2001-09-19
TR200003830T2 (tr)	2002-01-21
AU4360599A (en)	2000-01-10
US20020115211A1 (en)	2002-08-22
NO20006545L (no)	2001-02-21
ID27197A (id)	2001-03-08
ATE407363T1 (de)	2008-09-15

Publication	Publication Date	Title
Teh et al.	2016	What is the contribution of embryo-endometrial asynchrony to implantation failure?
Overstreet et al.	1976	Penetration of the zona pellucida of nonliving human oocytes by human spermatozoa in vitro
Abreu et al.	2018	Role of progesterone concentrations during early follicular development in beef cattle: I. Characteristics of LH secretion and oocyte quality
Pellicer et al.	1998	The follicular endocrine environment in stimulated cycles of women with endometriosis: steroid levels and embryo quality
Tesařík et al.	1988	Zona pellucida resistance to sperm penetration before the completion of human oocyte maturation
Takahashi et al.	1992	The kinetics of the acrosome reaction of human spermatozoa and its correlation with in vitro fertilization
Lee et al.	2011	The predictability of serum anti-Müllerian level in IVF/ICSI outcomes for patients of advanced reproductive age
Wiley et al.	2019	Effects of endogenous progesterone during ovarian follicle superstimulation on embryo quality and quantity in beef cows
Fried et al.	1998	Increase in transforming growth factor beta1 in ovarian follicular fluid following ovarian stimulation and in-vitro fertilization correlates to pregnancy.
AU760165B2 (en)	2003-05-08	Assay to indicate the presence of non-fertilisable ova
US20110002907A1 (en)	2011-01-06	Methods, Systems, Compositions And Dosage Forms For Diagnosing And Treating Male Infertility
van der Ven et al.	1989	Fertilization of human oocytes in capillary tubes with very small numbers of spermatozoa
Idil et al.	2004	Does granulosa cell apoptosis have a role in the etiology of unexplained infertility?
Avrech et al.	1997	Treatment variables in relation to oocyte maturation: lessons from a clinical micromanipulation-assisted in vitro fertilization program
Li et al.	2012	Ovarian adipocytokines are associated with early in vitro human embryo development independent of the action of ovarian insulin
US6649344B1 (en)	2003-11-18	Assay to indicate the presence of non-fertilizable ova
Heidenberg et al.	2022	In vitro fertilization cycle and embryo transfer outcomes in oligoanovulatory patients with hypothalamic hypogonadism vs. polycystic ovary syndrome and compared with normo-ovulatory patients
US8747294B2 (en)	2014-06-10	Assay of nitric oxide metabolites in the culture media of human preimplantation embryos
Cruz et al.	1999	Age and reproduction
Yapura et al.	2016	Synchronization of ovulation in cattle with an aromatase inhibitor–based protocol
VandeVoort et al.	2011	Primate preimplantation embryo is a target for relaxin during early pregnancy
Fontbonne	2008	In vivo ovulation, oocyte maturation and fertilisation in the bitch
CZ20004629A3 (cs)	2001-06-13	Test na přítomnost neplodného vajíčka
MXPA00012478A (en)	2002-07-25	Assay to indicate the presence of non-fertilisable ova
Inoue et al.	2024	The relationship between controlled ovarian stimulation protocol, meiotic spindle visibility, position of the meiotic spindle relative to the polar body in the human oocyte, and clinical outcomes following ICSI